Relative amounts of alternatively spliced products of PLC-β2.

Normalized first-strand cDNA from the patient (P) and healthy subjects (H) was amplified using PLC-β2 primers corresponding to 2575 nt to 2596 nt (forward) and 2864 nt to 2885 nt (reverse), flanking the alternative splicing site (2755 nt to 2799 nt). The products were subjected to gel electrophoresis, transferred to membrane, and subjected to phosphorimaging. Both splice variants were expressed in the patient but at decreased levels.